Advertisement

Journal of Hematopathology

, Volume 12, Issue 3, pp 157–162 | Cite as

Systemic mastocytosis with renal light chain amyloidosis: associated non-mast cell disorder or concurrent disease

  • Moussab Damlaj
  • Hanadi Ashi
  • Fouad Boulos
  • Hala Kfoury
  • Zaher ChakhachiroEmail author
Case Report

Abstract

Systemic mastocytosis with an associated hematological neoplasm (SM-AHN) is a rare diagnosis commonly associated with myeloid disorders. Herein, we describe the case of a 53-year-old female diagnosed with systemic mastocytosis (SM) in conjunction with renal light chain amyloidosis (AL) and smoldering myeloma. Although cytokines such as IL-6 may play a role in the proliferation of plasma cells, delays in the diagnosis of SM and paucity of relevant studies cast uncertainty on whether the associated disease is secondary to the mast cells or etiologically independent. To our knowledge, this is the first case of confirmed renal AL disease in conjunction with SM. We review and summarize the available literature describing SM in association with plasma cell disorders.

Keywords

Systemic mastocytosis Plasma cell disorder Amyloidosis 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Scherber RM, Borate U (2018) How we diagnose and treat systemic mastocytosis in adults. Br J Haematol 180(1):11–23CrossRefPubMedGoogle Scholar
  2. 2.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Pardanani A (2016) Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol 91(11):1146–1159CrossRefPubMedGoogle Scholar
  4. 4.
    Valent P, Sperr WR, Akin C (2010) How I treat patients with advanced systemic mastocytosis. Blood 116(26):5812–5817CrossRefPubMedGoogle Scholar
  5. 5.
    Stoecker MM, Wang E (2012) Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review. Arch Pathol Lab Med 136(7):832–838CrossRefPubMedGoogle Scholar
  6. 6.
    Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY et al (2009) Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 114(18):3769–3772CrossRefPubMedGoogle Scholar
  7. 7.
    Horny HP, Sotlar K, Sperr WR, Valent P (2004) Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 57(6):604–608CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Filanovsky K, Lev S, Haran M, Feldberg E, Bassous L, Berrebi A, Shtalrid M (2010) Systemic mastocytosis associated with smoldering multiple myeloma: an unexpected diagnosis in a patient with a rash. Leuk Lymphoma 51(6):1152–1154CrossRefPubMedGoogle Scholar
  9. 9.
    Hagen W, Schwarzmeier J, Walchshofer S, Zojer N, Chott A, Sillaber C, Ackermann J, Simonitsch I, Bühring HJ, Drach J, Lechner K, Horny HP, Valent P (1998) A case of bone marrow mastocytosis associated with multiple myeloma. Ann Hematol 76(3–4):167–174CrossRefPubMedGoogle Scholar
  10. 10.
    Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HM (2012) An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma. Clin Lymphoma Myeloma Leuk 12(6):459–462CrossRefPubMedGoogle Scholar
  11. 11.
    Sotlar K, Saeger W, Stellmacher F, Stahmer J, Jackle S, Valent P et al (2006) “Occult” mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis. J Clin Pathol 59(8):875–878CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Motwani P, Kocoglu M, Lorsbach RB (2009) Systemic mastocytosis in association with plasma cell dyscrasias: report of a case and review of the literature. Leuk Res 33(6):856–859CrossRefPubMedGoogle Scholar
  13. 13.
    Papadopoulou V, Ioannou S, Levidou G, Variami E, Kouzis P, Siakantaris M (2014) Systemic mastocytosis accompanied by a non-secretory plasma cell dyscrasia and nephrotic syndrome-level proteinuria in a 76-year-old patient. Acta Haematol 131(2):78–83CrossRefPubMedGoogle Scholar
  14. 14.
    Pullarkat ST, Sedarat F, Paquette R, Said J (2008) Systemic mastocytosis with plasma cell dyscrasia: report of a case. Leuk Res 32(7):1160–1163CrossRefPubMedGoogle Scholar
  15. 15.
    Stellmacher F, Sotlar K, Balleisen L, Valent P, Horny HP (2004) Bone marrow mastocytosis associated with IgM kappa plasma cell myeloma. Leuk Lymphoma 45(4):801–805CrossRefPubMedGoogle Scholar
  16. 16.
    Sasaki K, Chang A, Najafian B (2012) Indolent systemic mastocytosis associated with light chain deposition disease. Clin Kidney J 5(5):424–427CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ghanem S, Garcia G, Ying L, Hurford M, Odaimi M (2016) Systemic mastocytosis with smoldering multiple myeloma: report of a case. Case Rep Oncol Med 2016(3161768):1–6Google Scholar
  18. 18.
    Diamantidis MD, Myrou AD, Kaiafa GD, Kaloutsi V, Karayannopoulou G, Theodoridis A, Adamidou A, Papadopoulos A, Grekas D (2011) Aggressive systemic mastocytosis associated with mesangioproliferative glomerulonephritis. Acta Haematol 125(3):153–159CrossRefPubMedGoogle Scholar
  19. 19.
    Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY (2010) Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol 3(4):448–457PubMedPubMedCentralGoogle Scholar
  20. 20.
    Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S et al (2006) Mast cells in Waldenstrom’s macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 17(8):1275–1282CrossRefPubMedGoogle Scholar
  21. 21.
    Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson K, Sundstrom C, Enblad G, Nilsson G (2001) Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 114(3):616–623CrossRefPubMedGoogle Scholar
  22. 22.
    Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84(6):2008–2011CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lemoli RM, Fortuna A, Grande A, Gamberi B, Bonsi L, Fogli M, Amabile M, Cavo M, Ferrari S, Tura S (1994) Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. Br J Haematol 88(4):760–769CrossRefPubMedGoogle Scholar
  24. 24.
    Hameed A, Brady JJ, Dowling P, Clynes M, O’Gorman P (2014) Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis 7:33–42CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Fritz J, Fishman EK, Carrino JA, Horger MS (2012) Advanced imaging of skeletal manifestations of systemic mastocytosis. Skelet Radiol 41(8):887–897CrossRefGoogle Scholar
  26. 26.
    Schmidt-Hieber M, Perez-Andres M, Paiva B, Flores-Montero J, Perez JJ, Gutierrez NC, Vidriales MB, Matarraz S, San Miguel JF, Orfao A (2011) CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica 96(2):328–332CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Hematology & HSCT, Department of OncologyKing Abdulaziz Medical CityRiyadhKingdom of Saudi Arabia
  2. 2.King Saud bin Abdulaziz University for Health SciencesRiyadhKingdom of Saudi Arabia
  3. 3.King Abdullah International Medical Research CenterRiyadhKingdom of Saudi Arabia
  4. 4.Department of Pathology and Laboratory MedicineAmerican University of BeirutBeirutLebanon

Personalised recommendations